3SBio completes take-private deal

The Chinese biotech firm is quitting Nasdaq for a possible listing in Hong Kong.

3SBio completes take-private deal

Citic Private Equity and the chief executive of Nasdaq-listed 3SBio, a Chinese biotech firm, have completed a take-private deal that values the company at $370 million and paves the way for an offering in Hong Kong.

Under the terms of the merger agreement, holders of the company's ordinary shares and American depositary shares each representing seven shares will receive $2.39 a share or $16.70 per ADS.

That gives shareholders a 44%...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Print Edition

FinanceAsia Print Edition